Seminars in Ultrasound, CT and MRI
Volume 30, Issue 4 , Pages 315-325 , August 2009

Renal Cell Carcinoma: Recent Advances in Genetics and Imaging

  • Shaile Choudhary, MD

      Affiliations

    • Department of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • ,
  • Sunil Sudarshan, MD

      Affiliations

    • Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • ,
  • Peter L. Choyke, MD

      Affiliations

    • Molecular Imaging Program, National Cancer Institute, Bethesda, MD
    • ,
  • Srinivasa R. Prasad, MD

      Affiliations

    • Department of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, TX
    • Corresponding Author InformationAddress reprint requests to Srinivasa R. Prasad, MD, Department of Radiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229

References 

  1. In:  Eble JN,  Sauter G,  Epstein JI, et al. editor. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004;
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  3. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843–852
  4. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611–1623
  5. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612–624
  6. Prasad SR, Humphrey PA, Catena JR, et al. Common and uncommon histologic subtypes of renal cell carcinoma: Imaging spectrum with pathologic correlation. RadioGraphics. 2006;26:1795–1806discussion:1806-1710
  7. Prasad SR, Dalrymple NC, Surabhi VR. Cross-sectional imaging evaluation of renal masses. Radiol Clin North Am. 2008;46:95–111vi-vii
  8. Beer AJ, Dobritz M, Zantl N, et al. Comparison of 16-MDCT and MRI for characterization of kidney lesions. AJR Am J Roentgenol. 2006;186:1639–1650
  9. Mancini V, Battaglia M, Ditonno P, et al. Current insights in renal cell cancer pathology. Urol Oncol. 2008;26:225–238
  10. Polascik TJ, Bostwick DG, Cairns P. Molecular genetics and histopathologic features of adult distal nephron tumors. Urology. 2002;60:941–946
  11. Storkel S, Steart PV, Drenckhahn D, et al. The human chromophobe cell renal carcinoma: Its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56:237–245
  12. Lopez-Beltran A, Scarpelli M, Montironi R, et al. WHO classification of the renal tumors of the adults. Eur Urol. 2004;2006:798–805
  13. Poston CD, Jaffe GS, Lubensky IA, et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel–Lindau disease: Clinical and molecular genetic implications. J Urol. 1995;153:22–26
  14. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275
  15. Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the Von Hippel–Lindau protein. J Biol Chem. 1996;271:25492–25497
  16. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the Von Hippel–Lindau protein. Cancer Cells. 2002;1:237–246
  17. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of Von Hippel–Lindau function: Implications for targeting the HIF pathway. Cancer Res. 2006;66:6264–6270
  18. Neumann HP, Bender BU, Berger DP, et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel–Lindau disease compared to sporadic renal cell carcinoma. J Urol. 1998;160:1248–1254
  19. Kaelin WG. Kidney cancer: Now available in a new flavor. Cancer Cells. 2008;14:423–424
  20. Zbar B, Glenn G, Lubensky I, et al. Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. J Urol. 1995;153:907–912
  21. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–2350
  22. Schmidt L, Lubensky I, Linehan WM, et al. Hereditary papillary renal carcinoma: Pathology and pathogenesis. Contrib Nephrol. 1999;128:11–27
  23. Sudarshan S, Linehan WM. Genetic basis of cancer of the kidney. Semin Oncol. 2006;33:544–551
  24. Jefferson KP, Gillatt DA. Hereditary urological cancer syndromes. Nat Clin Pract Urol. 2007;4:218–226
  25. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–2490
  26. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406–410
  27. Merino MJ, Torres-Cabala C, Pinto P, et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31:1578–1585
  28. Birt AR, Hogg GR, Dubé WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol. 1977;113:1674–1677
  29. Toro JR, Glenn G, Duray P, et al. Birt-Hogg-Dubé syndrome: A novel marker of kidney neoplasia. Arch Dermatol. 1999;135:1195–1202
  30. Tickoo SK, Reuter VE, Amin MB, et al. Renal oncocytosis: A morphologic study of fourteen cases. Am J Surg Pathol. 1999;23:1094–1101
  31. Warren MB, Torres-Cabala CA, Turner ML, et al. Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod Pathol. 2004;17:998–1011
  32. Adley BP, Smith ND, Nayar R, et al. Birt-Hogg-Dubé syndrome: Clinicopathologic findings and genetic alterations. Arch Pathol Lab Med. 2006;130:1865–1870
  33. Nagy A, Zoubakov D, Stupar Z, et al. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. Int J Cancer. 2004;109:472–475
  34. Kim JK, Kim TK, Ahn HJ, et al. Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR Am J Roentgenol. 2002;178:1499–1506
  35. Jinzaki M, Tanimoto A, Mukai M, et al. Double-phase helical CT of small renal parenchymal neoplasms: Correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr. 2000;24:835–842
  36. Zhang J, Lefkowitz RA, Ishill NM, et al. Solid renal cortical tumors: Differentiation with CT. Radiology. 2007;244:494–504
  37. Outwater EK, Bhatia M, Siegelman ES, et al. Lipid in renal clear cell carcinoma: Detection on opposed-phase gradient-echo MR images. Radiology. 1997;205:103–107
  38. Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol. 1991;145:20–23discussion, 23-24
  39. Reznek RH. CT/MRI in staging renal cell carcinoma. Cancer Imaging. 2004;4(Spec No. A):S25–S32
  40. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  41. Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology. 1993;22:135–139
  42. Herts BR, Coll DM, Novick AC, et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol. 2002;178:367–372
  43. Shinmoto H, Yuasa Y, Tanimoto A, et al. Small renal cell carcinoma: MRI with pathologic correlation. J Magn Reson Imaging. 1998;8:690–694
  44. Roy C, Sauer B, Lindner V, et al. MR imaging of papillary renal neoplasms: Potential application for characterization of small renal masses. Eur Radiol. 2007;17:193–200
  45. Lesavre A, Correas JM, Merran S, et al. CT of papillary renal cell carcinomas with cholesterol necrosis mimicking angiomyolipomas. AJR Am J Roentgenol. 2003;181:143–145
  46. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: Clinicopathological features of 50 cases. J Urol. 1995;154:964–967
  47. Kondo T, Nakazawa H, Sakai F, et al. Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: A retrospective analysis on computed tomography and magnetic resonance imaging studies. Int J Urol. 2004;11:817–824
  48. Walther MM, Choyke PL, Weiss G, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol. 1995;153:913–916
  49. Linehan WM, Grubb RL, Coleman JA, et al. The genetic basis of cancer of kidney cancer: Implications for gene-specific clinical management. BJU Int. 2005;95(suppl 2):2–7
  50. Pavlovich CP, Walther MM, Choyke PL, et al. Percutaneous radio frequency ablation of small renal tumors: Initial results. J Urol. 2002;167:10–15
  51. Walther MM, Linehan WM. Re: Nephron sparing surgery for renal cell carcinoma in von Hippel–Lindau disease. J Urol. 1996;156:480–481
  52. Choyke PL, Pavlovich CP, Daryanani KD, et al. Intraoperative ultrasound during renal parenchymal sparing surgery for hereditary renal cancers: A 10-year experience. J Urol. 2001;165:397–400
  53. Motzer RJ. Renal cell carcinoma: A priority malignancy for development and study of novel therapies. J Clin Oncol. 2003;21:1193–1194
  54. Kaelin WG. The von Hippel–Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007;13:680s–684s
  55. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  56. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  57. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22:4442–4445
  58. Johnson JR, Williams G, Pazdur R. End points and US Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21:1404–1411
  59. Perini R, Choe R, Yodh AG, et al. Non-invasive assessment of tumor neovasculature: Techniques and clinical applications. Cancer Metastasis Rev. 2008;27:615–630
  60. Delahunt B, Eble JN, McCredie MR, et al. Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590–595

PII: S0887-2171(09)00021-3

doi: 10.1053/j.sult.2009.03.003

Seminars in Ultrasound, CT and MRI
Volume 30, Issue 4 , Pages 315-325 , August 2009

Article Tools

* Image Usage & Resolution